abound.2L
Showing 1 - 25 of >10,000
NSCLC Trial in Worldwide (nab-paclitaxel IV, CC-486, Duravalumab)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- nab-paclitaxel IV
- +2 more
-
San Francisco, California
- +33 more
Jan 24, 2022
Locally Advanced Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma Trial (RP3,
Not yet recruiting
- Locally Advanced Hepatocellular Carcinoma
- +2 more
- RP3
- +2 more
- (no location specified)
Feb 8, 2023
Colonic Disease, Intestinal Disease Trial (OST, 2L-PEG/Asc)
Not yet recruiting
- Colonic Disease
- Intestinal Disease
- (no location specified)
Feb 9, 2022
Esophageal Squamous Cell Carcinoma Trial (Paclitaxel, Irinotecan, Pembrolizumab)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Paclitaxel
- +4 more
-
Chuo-ku, Tokyo, JapanNational Cancer Center Hospital ( Site 3700)
Jan 31, 2023
Cabozantinib Post First-line Immuno-oncology Checkpoint
Completed
- Advanced Renal Cell Carcinoma (aRCC)
-
Glasgow, United Kingdom
- +8 more
Jun 30, 2022
1L-PEG-Asc Solution for Bowel Preparation in"Open Access"
Completed
- Bowel Preparation
- use of a very low-volume 1L-PEG plus ascorbate (plenvu) or low-volume 2L-PEG plus ascorbate (moviprep) for bowel preparation in open access colonoscopy
-
Carpi, Modena, ItalyAzienda USL Modena
Feb 15, 2022
Serplulimab in 2L and Above Treatment of Cervical Cancer
Recruiting
- Cervical Cancer
-
Jinan, Shandong, ChinaQilu Hospital of Shandong University
May 30, 2023
Type 2 Diabetes Trial in Lubbock (L-citrulline, Placebo)
Recruiting
- Type 2 Diabetes
- L-citrulline
- Placebo
-
Lubbock, TexasTTU Kinesiology and Sport Management Building
Aug 24, 2023
Advanced Solid Tumor Trial in Chengdu (Dual-targeting CLDN18.2 and PD-L1 CAR-T cells)
Not yet recruiting
- Advanced Solid Tumor
- Dual-targeting CLDN18.2 and PD-L1 CAR-T cells
-
Chengdu, Sichuan, ChinaWest China Hospital, Sichuan University
Oct 9, 2023
HER-2 Positive Advanced Solid Tumors Trial (D3L-001)
Not yet recruiting
- HER-2 Positive Advanced Solid Tumors
- D3L-001
- (no location specified)
Jul 20, 2023
NSCLC Trial in Guangzhou (Savolitinib, Docetaxel)
Not yet recruiting
- Non-small Cell Lung Cancer
-
Guangzhou, Guangdong, ChinaDepartment of Thoracic Surgery and Oncology, The First Affiliate
Mar 17, 2023
Diabetic Peripheral Neuropathic Pain Trial in Luoyang (HSK16149 20mg BID)
Recruiting
- Diabetic Peripheral Neuropathic Pain
- HSK16149 20mg BID
-
Luoyang, Henan, ChinaThe First Affiliated Hospital of Henan University of Science and
Nov 2, 2023
Heart Failure Trial in Hamilton (Virtual HF Care, Routine HF Care)
Recruiting
- Heart Failure
- Virtual HF Care
- Routine HF Care
-
Hamilton, Onatrio, Canada
- +2 more
Feb 1, 2023
Nerve Injury Trial in Hamilton (Temporary Peripheral Nerve Stimulator)
Recruiting
- Nerve Injury
- Temporary Peripheral Nerve Stimulator
-
Hamilton, Ontario, Canada
- +2 more
Feb 1, 2023
Metastatic Microsatellite-stable Colorectal Cancer Trial (LB-100, Atezolizumab)
Not yet recruiting
- Metastatic Microsatellite-stable Colorectal Cancer
- (no location specified)
Sep 1, 2023
Anastomotic Leak Trial in Hamilton (Stream™ Platform, Stream™ Platform with Risk Score Omitted)
Not yet recruiting
- Anastomotic Leak
- Stream™ Platform
- Stream™ Platform with Risk Score Omitted
-
Hamilton, Ontario, Canada
- +1 more
Aug 8, 2023
Fracture, Frailty, Aging Trial in Saint John (Patient Navigation)
Recruiting
- Fracture
- +2 more
- Patient Navigation
-
Saint John, New Brunswick, CanadaSaint John Regional Hospital
Oct 25, 2023
B-cell Non-Hodgkin Lymphoma Trial in Worldwide (Mosunetuzumab (IV), Mosunetuzumab (SC), Polatuzumab vedotin)
Recruiting
- B-cell Non-Hodgkin Lymphoma
- Mosunetuzumab (IV)
- +4 more
-
Birmingham, Alabama
- +28 more
Jan 6, 2023
Lung Cancer, Colorectal Cancer Trial in Beijing (18F-FDG)
Recruiting
- Lung Cancer
- Colorectal Cancer
-
Beijing, ChinaBeijing Cancer Hospital
Mar 27, 2023
Solid Tumor Trial (BS006 Injection)
Not yet recruiting
- Solid Tumor
- BS006 Injection
- (no location specified)
Jul 3, 2023
Metastatic Gastric Cancer, PD-L1 Gene Amplification, FGFR2 Amplification Trial in New York (Nivolumab, Capecitabine,
Recruiting
- Metastatic Gastric Cancer
- +2 more
- Nivolumab
- +2 more
-
New York, New YorkBureau for Cancer Research
May 10, 2023
Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors, RC48 Trial in Guanzhou (RC48+Tislelizumab+carboplatin,
Not yet recruiting
- Non Small Cell Lung Cancer
- +3 more
- RC48+Tislelizumab+carboplatin
- +2 more
-
Guanzhou, ChinaSunYat-senU
May 5, 2023